5.26
Schlusskurs vom Vortag:
$5.02
Offen:
$5
24-Stunden-Volumen:
4.56M
Relative Volume:
1.08
Marktkapitalisierung:
$1.23B
Einnahmen:
$251.85M
Nettoeinkommen (Verlust:
$-72.58M
KGV:
-16.78
EPS:
-0.3134
Netto-Cashflow:
$-63.80M
1W Leistung:
+9.24%
1M Leistung:
+1.35%
6M Leistung:
-8.84%
1J Leistung:
-16.64%
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Vergleichen Sie ARDX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ARDX
Ardelyx Inc
|
5.26 | 1.23B | 251.85M | -72.58M | -63.80M | -0.3134 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
2025-03-04 | Eingeleitet | BTIG Research | Buy |
2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
2021-03-23 | Eingeleitet | Wedbush | Outperform |
2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-10-20 | Fortgesetzt | Citigroup | Buy |
2020-02-18 | Fortgesetzt | Jefferies | Buy |
2020-02-12 | Eingeleitet | Citigroup | Buy |
2020-02-10 | Eingeleitet | Cowen | Outperform |
2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
2018-08-24 | Eingeleitet | Jefferies | Buy |
2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
2017-11-29 | Bestätigt | Citigroup | Buy |
2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Ardelyx Announces Three Abstracts Accepted For Poster Presentations At Digestive Disease Week 2025 Conference - marketscreener.com
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference - The Manila Times
Groundbreaking IBSRELA Pediatric Safety Data Headlines 3 New Studies at Digestive Disease Week 2025 - Stock Titan
(ARDX) Proactive Strategies - news.stocktradersdaily.com
Lobbying Update: $620,000 of ARDELYX INC. lobbying was just disclosed - Nasdaq
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 - The Manila Times
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 | ARDX Stock News - GuruFocus
Ardelyx, Inc. Schedules Conference Call to Discuss Q1 2025 Financial Results and Business Update - Nasdaq
Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
April 2025's Top Penny Stocks To Watch - Yahoo Finance
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Stride Announces Date for Third Quarter Fiscal Year 2025 Earnings Call - The Globe and Mail
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings - The Manila Times
Ardelyx reveals new findings on CKD treatment XPHOZAH at NKF event - Investing.com Canada
Ardelyx reveals new findings on CKD treatment XPHOZAH at NKF event By Investing.com - Investing.com South Africa
Ontario Teachers' Appoints Terry Hickey as Chief Technology Officer - The Globe and Mail
Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Breakthrough: New Analysis Reveals Better Outcomes for First-in-Class Kidney Drug XPHOZAH - Stock Titan
Ardelyx CEO Michael Raab sells $191k in stock - Investing.com
Ardelyx CEO Michael Raab sells $191k in stock By Investing.com - Investing.com UK
Ardelyx stock hits 52-week low at $4.29 amid challenges By Investing.com - Investing.com South Africa
Ardelyx stock hits 52-week low at $4.29 amid challenges - Investing.com Australia
How To Trade (ARDX) - news.stocktradersdaily.com
Levi's (LEVI) Reports Q1: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx, Inc. LawsuitARDX - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx LawsuitARDX - ACCESS Newswire
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - The Manila Times
First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results - Stock Titan
Commit To Purchase Ardelyx At $4, Earn 20.5% Annualized Using Options - Nasdaq
Institutional owners may take dramatic actions as Ardelyx, Inc.'s (NASDAQ:ARDX) recent 6.4% drop adds to one-year losses - simplywall.st
How to Take Advantage of moves in (ARDX) - news.stocktradersdaily.com
Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Ardelyx Requests to Dismiss Class Action Filed by Investors - TradingView
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - Marketscreener.com
ARDELYX INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Trading (ARDX) With Integrated Risk Controls - news.stocktradersdaily.com
Ardelyx honors inaugural Derek Forfang award winners By Investing.com - Investing.com Australia
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth - Investing.com
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth By Investing.com - Investing.com UK
Ardelyx honors inaugural Derek Forfang award winners - Investing.com India
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):